Navigation Links
Exalenz Bioscience Expands Market Coverage for the BreathID Breath Test System
Date:5/27/2010

Agreement with Leading Manufacturers Representative Firm Brings 10-minute, Non-radioactive 13C-urea Breath Testing to the Western U.S. States.

Newfields, NH (PRWEB) May 27, 2010 -- Exalenz Bioscience, a medical device company specializing in the diagnosis and monitoring of gastroenterological and liver related diseases, today announced it has entered into a strategic relationship with Representations, LLC, a leading Manufacturers Representative organization, to promote the BreathID® Breath Test System and Exalenz’ full line of H. pylori diagnostic solutions.

The BreathID® System is a breath test platform capable of analyzing parts-per-million changes in carbon 13 and carbon 12 ratios in a patient's breath. This system is distinguished by its ability to continuously measure breath, resulting in the fastest breath test available (10 minutes), its single-button operation for ease-of-use, and its documented superior sensitivity and specificity.

Representations has operated as a Medical Manufacturers Representative firm for 55 years. The company’s sales representatives span the thirteen western-most states and will provide focused coverage for Exalenz under the management of Exalenz’ Region Sales Managers.

“We are excited to be working with Representations,” said Dennis Boyle, Vice President and National Manager for Exalenz. “Representations has been in business for over 55 years serving and servicing the Physician’s Office market. They bring a strong history of selling capital equipment that provides unique solutions to the primary care marketplace. We look forward to a highly successful relationship with the team.”

Helicobacter pylori is a bacterium that lives in the stomach and small intestine and can cause symptoms such as bloating, and heartburn, and more severe conditions, such as gastritis, ulcers and, in some cases, gastric cancer. Conclusively eradicating H. pylori through treatment depends on an accurate diagnosis of active H. pylori infection. According to the American College of Gastroenterology’s (ACG) 2007 guidelines, the test most widely used by physicians (the Blood Antibody Test) is “no better than a coin toss in predicting active infection.” Urea Breath Testing – and the BreathID® System – have been proven to accurately and reliably detect active infection and their use is supported by the ACG clinical guidelines.

Exalenz offers physicians two distinct Urea Breath Testing solutions. The first is the Hp FasTest™, which is an in-office testing platform performed using a dedicated BreathID device that is located in the physician's office. With this option, H. pylori testing can be done on the spot with results received in around 10 minutes. The company also offers a send-in service (using the Hp BagTestTM), where collected breath samples are sent to a dedicated breath testing center for analysis.

“We believe Exalenz’ solutions for H. pylori detection have a place in every primary care physician practice,” said Ross J. Rankin, President of Representations. “There is a significant need for accurate, point-of-care testing solutions for H. pylori. We are excited to bring the BreathID® System and service to physicians in our region."

About Exalenz
Exalenz Bioscience specializes in the diagnosis and monitoring of gastroenterological and liver related diseases, using its proprietary BreathID® Breath Test platform. For additional information, please visit the company's website: www.exalenz.com and the website dedicated to the H. pylori field: www.helicobacterpyloritest.com.

About Representations
Representations, LLC, has operated as a Medical Manufacturers Representative firm for 55 years since its founding by John Rankin. The company represents quality medical manufacturers in the medical surgical and home care fields. Headquartered in Santa Ynez, California, Representations’ sales representatives cover the thirteen western United States. For more information, please visit the company’s website: www.representations.com.

Statements in this release of product performance, future expectations, plans and prospects may include forward looking statements. The Company's actual results, performance and execution may differ materially from those discussed, based on a variety of factors, including, among others: uncertainties with respect to market acceptance of the Company's products, risks associated with competition and competitive pricing pressures and economic conditions generally.

Contact
For more information, please call Sean Hanlon at 1-888-EXALENZ or email pr (at) exalenz (dot) com.

###

Read the full story at http://www.prweb.com/releases/2010/05/prweb4057324.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Digital Pathology Services Firm Flagship Biosciences Appoints New CEO
2. Quincy Bioscience Launches HOPETrials.com; Research Studies More Accessible For Participants
3. Southridge LLC Provides Equity Capital Through Private Agreement with PuraMed Bioscience
4. Euthymics Bioscience Collaborates with GlobalSign and SafeNet to Provide an FDA Approved Electronic Signature Solution
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results
6. Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
7. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
8. Thriving Bioscience Region Leaves Its Mark
9. NYC Chiropractor Expands Practice with Therapy for Muscle and Overuse Injuries
10. Ross Group Inc Expands Sales of Membership and Customer Relationship Management Software
11. Tainted Lettuce Recall Expands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions ... definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... this summer’s edition of “Vision & Hearing,” advocating for active, healthy lifestyles and ... on resources available for individuals with hearing impairments and shares the latest innovations ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... handling handheld devices. Through an educational webinar, they will present the line of ... chance to learn how easy you can automate everyday pipetting tasks. , Ideal ...
(Date:8/18/2017)... ... August 18, 2017 , ... Hernandez Insurance Agencies, a northern ... the greater DC region, is inaugurating a “New Leash On Life” charity initiative ... training them to be companions for veterans in need. , The Semper K9 ...
(Date:8/18/2017)... ... 18, 2017 , ... Moore Insurance, a Houston area agency ... is launching a regional charity effort to provide publicity assistance and generate donations ... Tumor Foundation (PBTF) has raised nearly $30 million in donations that has been ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... ended June 30, 2017, and updated its financial outlook ... For the fiscal third quarter, Hill-Rom reported earnings ... diluted share in the prior-year period. These results reflect ... diluted share primarily related to the non-cash write-down of ...
(Date:7/27/2017)... July 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... for the second-quarter 2017 and updated financial guidance for ... Second-Quarter 2017 Highlights Reported net sales ... the prior-year quarter. Net sales at constant currency (organic) ... EPS was $0.51, compared to $0.60 in the prior-year ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology: